Clinical Trial Update: Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms [Phase 1]

View source ↗

Summary

Phase 1 study of LY2784544 testing alternative dosing in patients with myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Myelofibrosis
• Polycythemia Vera

Drugs mentioned

• LY2784544

Snippet

Sponsor: Eli Lilly and Company | Conditions: Myeloproliferative Neoplasms of, Polycythemia Vera | Phase 1 | Status: COMPLETED